Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cencora, Inc. Common Stock (NY:COR)

277.41 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Apr 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cencora, Inc. Common Stock

< Previous 1 2 3 4 5 Next >
Cencora Announces Common Share Repurchase From Walgreens Boots Alliance and Raises Fiscal 2024 Guidance
From Cencora
Via Business Wire
Here's How Much $1000 Invested In Cencora 5 Years Ago Would Be Worth Today
Via Benzinga
Unveiling 4 Analyst Insights On Cencora
Via Benzinga
COR Stock Earnings: Cencora Beats EPS, Misses Revenue for Q2 2024
COR stock results show that Cencora beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. 
Via InvestorPlace
Cencora Reports Fiscal 2024 Second Quarter Results
From Cencora
Via Business Wire
$100 Invested In This Stock 10 Years Ago Would Be Worth $400 Today
Via Benzinga
If You Invested $1000 In This Stock 10 Years Ago, You Would Have $3,700 Today
Via Benzinga
$1000 Invested In Cencora 5 Years Ago Would Be Worth This Much Today
Via Benzinga
3 High-Quality Stocks That Will Never Put You in the Red
These quality stocks have real staying power and the ability to generate consistent profits and growth over the long haul. 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Cencora Announces Date and Time for Second Quarter Fiscal 2024 Earnings Release
From Cencora
Via Business Wire
Here's How Much $100 Invested In Cencora 10 Years Ago Would Be Worth Today
Via Benzinga
Cencora Announces Leadership Succession Plan
From Cencora
Via Business Wire
Here's How Much You Would Have Made Owning Cencora Stock In The Last 5 Years
Via Benzinga
Critical Insights From Cencora Analyst Ratings: What You Need To Know
Via Benzinga
Here's How Much $1000 Invested In Cencora 5 Years Ago Would Be Worth Today
Via Benzinga
US Federal Trade Commission Investigates Drug Shortages Amid Allegations Of Market Manipulation
FTC probes chemotherapy shortages, scrutinizing drug distributors and hospital groups. Root causes of drug shortages under scrutiny. Industry defends practices. 
Via Benzinga
Why Walgreens Boots Alliance Stock Slumped 13.6% in January
The pharmacy giant ended an era. 
Via The Motley Fool
Cencora Announces Common Share Repurchase From Walgreens Boots Alliance
From Cencora
Via Business Wire
Walgreens Boots Alliance Sells Shares of Cencora For $992 Million of Proceeds
From Walgreens Boots Alliance
Via Business Wire
Wednesday Is Your Last Chance To Buy Cencora Before The Dividend Payout
Via Benzinga
$1000 Invested In This Stock 15 Years Ago Would Be Worth $12,000 Today
Via Benzinga
Peering Into Cencora's Recent Short Interest
Via Benzinga
Cencora Closes $500 Million Senior Notes Offering
From Cencora
Via Business Wire
Cencora Prices $500 Million 5.125% Senior Notes Due 2034
From Cencora
Via Business Wire
Drug Wholesale Firm Cencora Starts 2024 With Strong Growth, Lifts Annual Forecast On Commercial COVID-19 Vaccine Distribution
Cencora reports Q1 2024 results with adjusted EPS at $3.28 and revenue of $72.3 billion. Explore the company's fiscal year 2024 guidance and growth projections. 
Via Benzinga
Exposures COVID-19
Cencora Reports Fiscal 2024 First Quarter Results
From Cencora
Via Business Wire
How Is The Market Feeling About Cencora?
Via Benzinga
Earnings Scheduled For January 31, 2024
Companies Reporting Before The Bell • Novartis (NYSE:NVS) is likely to report quarterly earnings at $1.68 per share on revenue of $11.56 billion. 
Via Benzinga
Chart Of The Day: Cencora - Name Changed To Protect The Innocent?
Cencora, Inc. sources and distributes pharmaceutical products. 
Via Talk Markets
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.